| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.29 | 1e-10 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.21 | 2e-05 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.2 | 0.0003 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.12 | 0.004 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.13 | 0.004 |